Key Takeaways
- Opportunity is diagnosed, eligible and reachable patients—not prevalence.
- Assess who controls adoption across specialists, institutions, payers and support channels.
- Evaluate the competitive market at launch, not only today’s market.
- Feasibility of commercialization is part of opportunity—not separate from it.
Emerging biotechnology companies and investors often need a clearer answer to a basic question: how large is the real commercial opportunity?
Forecast precision can create false confidence. The stronger discipline is pressure-testing the assumptions underneath the forecast. That is the purpose of commercial due diligence and related opportunity assessment.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
